{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "One percent of patients account for more than 25 percent of health care spending among the privately insured, according to a study.", "headline": {"seo": "At-Risk Patients Gain Attention of Health Insurers", "main": "At-Risk Patients Gain Attention of Health Insurers", "print_headline": "At Risk and Under Scrutiny"}, "abstract": "Study finds one percent of patients account for more than 25 percent of health care spending among the privately insured; notes their medical bills average nearly $100,000 annually and they are typically people who suffer from chronic and increasingly common diseases like diabetes and high blood pressure.", "print_page": "1", "word_count": "1019", "_id": "515b6d52fdc59278db00a128", "snippet": "One percent of patients account for more than 25 percent of health care spending among the privately insured, according to a study.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/02/28/health/at-risk-patients-gain-attention-of-health-insurers.html", "multimedia": [{"subtype": "xlarge", "url": "images/2012/02/28/business/DIABETES/DIABETES-articleLarge.jpg", "height": 350, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2012/02/28/business/DIABETES/DIABETES-articleLarge.jpg", "xlargeheight": "350"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2012/02/28/business/DIABETES/DIABETES-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2012/02/28/business/DIABETES/DIABETES-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Diabetes", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Aetna Inc", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "CIGNA Corporation", "is_major": "N", "rank": "4", "name": "organizations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Reed", "lastname": "ABELSON"}], "original": "By REED ABELSON"}, "document_type": "article", "pub_date": "2012-02-28T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "Many people are unaware that dozens of painkillers, antihistamines and psychiatric medications - from drugstore staples to popular antidepressants - can adversely affect brain function, mostly in the elderly. Regular use of multiple medications that have this effect has been linked to cognitive impairment and memory loss. Called anticholinergics, the drugs block the action of the neurotransmitter acetylcholine, sometimes as a direct action, but often as a side effect. Acetylcholine is a chemical messenger with a range of functions in the body, memory production and cognitive function among them.", "headline": {"main": "The Consumer: A Cocktail Of Drugs May Cloud The Brain", "kicker": "WELL"}, "abstract": "Series of new studies finds that the cumulative use of drugs with anticholinergic properties, which can include common painkillers, antihistamines and psychiatric medications, can adversely affect brain function, especially in the elderly; regular use of multiple medications that have this effect has been linked to cognitive impairment and memory loss. Drawing (M)", "print_page": "5", "word_count": 1132, "_id": "4fd2ae1f8eb7c8105d89bf91", "snippet": "Many people are unaware that dozens of painkillers, antihistamines and psychiatric medications - from drugstore staples to popular antidepressants - can adversely affect brain function, mostly in the elderly. Regular use of multiple medications that...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9B05E4D81E31F93BA15751C0A9649D8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "ELDERLY"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "BRAIN"}, {"name": "subject", "value": "MEMORY"}, {"name": "subject", "value": "PAIN-RELIEVING DRUGS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}], "byline": {"person": [{"firstname": "Roni", "middlename": "Caryn", "lastname": "RABIN", "rank": 1, "role": "reported", "organization": ""}], "original": "By RONI CARYN RABIN"}, "document_type": "article", "pub_date": "2012-02-28T00:00:00Z", "section_name": "Health; Science"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage.", "headline": {"seo": "Austerity in Europe Puts Pressure on Drug Companies", "main": "Austerity in Europe Puts Pressure on Drug Companies", "print_headline": "Austerity in Europe Puts Pressure on Drug Companies"}, "abstract": null, "print_page": "", "word_count": "1019", "_id": "53f3e9af79881034aaf5accc", "snippet": "Budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/02/24/business/austerity-in-europe-puts-pressure-on-drug-companies.html", "multimedia": [{"subtype": "thumbnail", "url": "images/2012/02/24/business/Pharma/Pharma-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2012/02/24/business/Pharma/Pharma-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "European Sovereign Debt Crisis (2010- )", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Novartis AG", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "AstraZeneca PLC", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "Europe", "is_major": "N", "rank": "5", "name": "glocations"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Stephanie", "lastname": "NOVAK"}], "original": "By STEPHANIE NOVAK"}, "document_type": "article", "pub_date": "2012-02-24T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage.", "headline": {"seo": "Austerity in Europe Puts Pressure on Drug Companies", "main": "Austerity in Europe Puts Pressure on Drug Prices", "print_headline": "Austerity in Europe Puts Pressure on Drug Prices"}, "abstract": "Profits at pharmaceutical companies have been declining or showing little growth in past year as austerity measures across Europe lead to cuts in health care spending; budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage.", "print_page": "6", "word_count": "1019", "_id": "515b6e60fdc59278db00a287", "snippet": "Budget cuts mean governments are not willing to pay as much for pills, and new laws in some countries require companies to prove drugs are effective or risk losing coverage.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/02/24/business/global/drug-companies-feel-price-pressure.html", "multimedia": [], "subsection_name": "Global Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "European Sovereign Debt Crisis (2010- )", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Politics and Government", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Economic Conditions and Trends", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Europe", "is_major": "N", "rank": "5", "name": "glocations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Stephanie", "lastname": "NOVAK"}], "original": "By STEPHANIE NOVAK"}, "document_type": "article", "pub_date": "2012-02-24T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "OpEd", "lead_paragraph": "Our Catholic organization hasn\u2019t strayed from our values. And we won\u2019t, even though our commitment has put us at odds with the Obama administration.", "headline": {"seo": "Why EWTN Won&#8217;t Cover Contraception", "main": "Contraception, Against Conscience", "kicker": "Op-Ed Contributor", "print_headline": "Contraception, Against Conscience", "content_kicker": "Op-Ed Contributor"}, "abstract": "Op-Ed article by Michael P Warsaw, president of the nonprofit EWTN Global Catholic Network, uses his organization's situation to demonstrate how the requirement that organizations provide their employees with contraceptive and sterilization procedures violates religious liberty; argues that it also imperils the financial viability of any organization that chooses not to provide such services to their employees.", "print_page": "23", "word_count": "690", "_id": "515b6ee1fdc59278db00a31d", "snippet": "Our Catholic organization hasn\u2019t strayed from our values. And we won\u2019t, even though our commitment has put us at odds with the Obama administration.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/02/22/opinion/why-ewtn-wont-cover-contraception.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Birth Control and Family Planning", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Roman Catholic Church", "is_major": "Y", "rank": "3", "name": "organizations"}, {"value": "Fines (Penalties)", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Angelica (Mother)", "is_major": "N", "rank": "5", "name": "persons"}, {"value": "Obama, Barack", "is_major": "N", "rank": "6", "name": "persons"}], "byline": {"contributor": "", "person": [{"firstname": "Michael", "middlename": "P.", "lastname": "WARSAW", "rank": 1, "role": "reported", "organization": ""}], "original": "By MICHAEL P. WARSAW"}, "document_type": "article", "pub_date": "2012-02-22T00:00:00Z", "section_name": "Opinion"}], "meta": {"hits": 5, "offset": 0, "time": 29}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}